Skip to main content
Erschienen in: Clinical and Translational Oncology 7/2017

27.01.2017 | Research Article

Topography of the sentinel node according to the affected lobe in lung cancer

verfasst von: J. M. Galbis-Caravajal, A. Lafuente-Sanchis, M. Estors-Guerrero, N. Martinez-Hernández, C. Fuster-Diana, A. Cremades, Á. Zúñiga

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this study is to describe the anatomic location of the sentinel lymph node (SLN) of patients with lung carcinoma and to analyze its relationship with the characteristics of the tumor.

Patients and methods

98 Stage I lung cancer patients were included in the study. SLN was marked just after performing the thoracotomy by injecting peritumorally 0.25 mCi of nanocolloid of albumin (Nanocol1) labeled with Tc-99 m in 0.3 ml, and later, it was resected. For SLN micrometastasis analysis, CEACAM5, BPIFA1, and CK7 gene expression at mRNA level was studied. Possible relation between tumor characteristics and SLN location was analyzed.

Results

While most of the SLN were located in hilar area, we find a significantly higher number of SLN located in mediastinal stations when the lesion is in the left upper lobe (LUL). This difference disappears in the group of SLN with a positive result in the micrometastasis study. Regarding tumor size, squamous tumors and tumors located in the left lower lobe (LLL) were found significantly larger.

Conclusion

The location of the SLN in patients with stage I lung cancer is predominantly hilar, being less consistent in the left hemithorax. The tumor size or histological type is not variables that affect this distribution. The distribution of SLNs with a positive result in the analysis of micrometastasis suggests further spread to the hilar areas when the lesion is in the LUL and to the mediastinal zones when it is in the LLL.
Literatur
1.
Zurück zum Zitat Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.PubMed Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.PubMed
2.
Zurück zum Zitat American Thoracic Society. Clinical staging of primary lung cancer: American Thoracic Society node mapping scheme. Am Rev Respir Dis. 1983;127:659–69.CrossRef American Thoracic Society. Clinical staging of primary lung cancer: American Thoracic Society node mapping scheme. Am Rev Respir Dis. 1983;127:659–69.CrossRef
3.
Zurück zum Zitat Ou S-HI, Zell JA. Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. J Thorac Oncol. 2008;3:880–6.CrossRefPubMed Ou S-HI, Zell JA. Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. J Thorac Oncol. 2008;3:880–6.CrossRefPubMed
4.
Zurück zum Zitat Varlotto JM, Recht A, Nikolov M, Flickinger JC, de Camp MM. Extent of lymphadenectomy and outcome for patients with stage I non-small cell lung cancer. Cancer. 2009;115:851–8.CrossRefPubMed Varlotto JM, Recht A, Nikolov M, Flickinger JC, de Camp MM. Extent of lymphadenectomy and outcome for patients with stage I non-small cell lung cancer. Cancer. 2009;115:851–8.CrossRefPubMed
5.
Zurück zum Zitat Whitson B, Groth S, Maddaus M. Surgical assessment and intraoperative management of mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg. 2007;84:1059–65.CrossRefPubMed Whitson B, Groth S, Maddaus M. Surgical assessment and intraoperative management of mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg. 2007;84:1059–65.CrossRefPubMed
6.
Zurück zum Zitat Galbis J, Cremades A, Zuñiga A, Estors M, Tembl Ferrairó A, Martínez-Hernández N, et al. El ganglio centinela en el carcinoma pulmonar. Estudio molecular tras detección con radio isótopo. Cir Esp. 2014;92:1–3. Galbis J, Cremades A, Zuñiga A, Estors M, Tembl Ferrairó A, Martínez-Hernández N, et al. El ganglio centinela en el carcinoma pulmonar. Estudio molecular tras detección con radio isótopo. Cir Esp. 2014;92:1–3.
7.
Zurück zum Zitat Benlloch S, Galbis JM, Alenda C, Peiró FM, Sánchez-Ronco M, Rodríguez-Paniagua JM, et al. Expression of molecular markers in mediastinal nodes from resected stage I non-small cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases. Ann Oncol. 2009;20:91–7.CrossRefPubMed Benlloch S, Galbis JM, Alenda C, Peiró FM, Sánchez-Ronco M, Rodríguez-Paniagua JM, et al. Expression of molecular markers in mediastinal nodes from resected stage I non-small cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases. Ann Oncol. 2009;20:91–7.CrossRefPubMed
8.
Zurück zum Zitat Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy. Results of the Randomized, Prospective American College of Surgeons Oncology Group Z0030 Trial. Chest. 2011;139:1124–9.CrossRefPubMed Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy. Results of the Randomized, Prospective American College of Surgeons Oncology Group Z0030 Trial. Chest. 2011;139:1124–9.CrossRefPubMed
9.
Zurück zum Zitat Liptay M, Masters G, Winchester D, Eldelman BL, Garrido BJ, Hirschtritt TR, et al. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg. 2000;70:384–90.CrossRefPubMed Liptay M, Masters G, Winchester D, Eldelman BL, Garrido BJ, Hirschtritt TR, et al. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg. 2000;70:384–90.CrossRefPubMed
10.
Zurück zum Zitat Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, et al. On behalf of the International Association for the Study of Lung Cancer International Staging Committee the IASLC lung cancer staging project. Data elements for the prospective project. J Thorac Oncol 2009;4:679–83. Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, et al. On behalf of the International Association for the Study of Lung Cancer International Staging Committee the IASLC lung cancer staging project. Data elements for the prospective project. J Thorac Oncol 2009;4:679–83.
11.
Zurück zum Zitat Ignatius S, Zell J. Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. J Thorac Oncol. 2008;4:880–6. Ignatius S, Zell J. Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. J Thorac Oncol. 2008;4:880–6.
12.
Zurück zum Zitat Xu F, Qi L, Yue D, Wang Ch. The effect of the extent of lymph node dissection for stage IA non-small cell lung cancer on patients’ disease free survival. Clin Lung Cancer. 2013;14(2):181–7.CrossRefPubMed Xu F, Qi L, Yue D, Wang Ch. The effect of the extent of lymph node dissection for stage IA non-small cell lung cancer on patients’ disease free survival. Clin Lung Cancer. 2013;14(2):181–7.CrossRefPubMed
13.
Zurück zum Zitat Nomori H, Kohno M, Izumi Y, Ohtsuka T, Asakura K. Sentinel nodes in lung cancer: review of our 10-year experience. Surg Today. 2011;41:889–95.CrossRefPubMed Nomori H, Kohno M, Izumi Y, Ohtsuka T, Asakura K. Sentinel nodes in lung cancer: review of our 10-year experience. Surg Today. 2011;41:889–95.CrossRefPubMed
14.
Zurück zum Zitat Little AG, de Hoyos A, Kirgan DM, Arcomno TR, Murray KD. Intraoperative lymphatic mapping for non-small cell lung cancer: the sentinel nodel technique. J Thorac Cardiovasc Surg. 1999;117:220–4.CrossRefPubMed Little AG, de Hoyos A, Kirgan DM, Arcomno TR, Murray KD. Intraoperative lymphatic mapping for non-small cell lung cancer: the sentinel nodel technique. J Thorac Cardiovasc Surg. 1999;117:220–4.CrossRefPubMed
15.
Zurück zum Zitat Riquet M, Bagan P, Le Pimpec BF, Banu E, Scotte F, Foucault C, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg. 2007;84:1818–24.CrossRefPubMed Riquet M, Bagan P, Le Pimpec BF, Banu E, Scotte F, Foucault C, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg. 2007;84:1818–24.CrossRefPubMed
16.
Zurück zum Zitat Puma B. Isolated mediastinal skip metastasis in lung cancer: is it real N2 disease? J Thorac Cardiovasc Surg. 2005;129:235.CrossRefPubMed Puma B. Isolated mediastinal skip metastasis in lung cancer: is it real N2 disease? J Thorac Cardiovasc Surg. 2005;129:235.CrossRefPubMed
17.
Zurück zum Zitat Misthos P, Sepsas E, Kokotsakis J, Skottis I, Lioulias A. The significance of one station N2 disease in the prognosis of patients with non-small cell lung cancer. Ann Thorac Surg. 2008;86:1626–31.CrossRefPubMed Misthos P, Sepsas E, Kokotsakis J, Skottis I, Lioulias A. The significance of one station N2 disease in the prognosis of patients with non-small cell lung cancer. Ann Thorac Surg. 2008;86:1626–31.CrossRefPubMed
18.
Zurück zum Zitat Benoit L, Anusca A, Ortega-Deballon P, Cheynel N, Bernard A, Favre JP. Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non- small-cell lung carcinoma. Eur J Surg Oncol. 2006;32:583–7.CrossRefPubMed Benoit L, Anusca A, Ortega-Deballon P, Cheynel N, Bernard A, Favre JP. Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non- small-cell lung carcinoma. Eur J Surg Oncol. 2006;32:583–7.CrossRefPubMed
19.
Zurück zum Zitat Tomaszek SC, Kim Y, Cassivi SD, Jensen MR, Shen KH, Nichols FC, et al. Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg. 40(5):1151–6. Tomaszek SC, Kim Y, Cassivi SD, Jensen MR, Shen KH, Nichols FC, et al. Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg. 40(5):1151–6.
20.
Zurück zum Zitat Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the 7th edition TNM classification. Chest 2011;140(6):1494–502. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the 7th edition TNM classification. Chest 2011;140(6):1494–502.
21.
Zurück zum Zitat Karamustafaoglu YA, Yoruk Y, Yanik F, Sarikaya A. Sentinel lymph node mapping in patients with operable non-small cell lung cancer. J Thorac Dis. 2013;5(3):317–20.PubMedPubMedCentral Karamustafaoglu YA, Yoruk Y, Yanik F, Sarikaya A. Sentinel lymph node mapping in patients with operable non-small cell lung cancer. J Thorac Dis. 2013;5(3):317–20.PubMedPubMedCentral
22.
Zurück zum Zitat Pulte D, Li E, Crawford BK, Newman E, Alexander A, Mustalish DC, et al. Sentinel lymph node mapping and molecular staging in nonsmall cell lung carcinoma. Cancer. 2005;104(7):1453–61.CrossRefPubMed Pulte D, Li E, Crawford BK, Newman E, Alexander A, Mustalish DC, et al. Sentinel lymph node mapping and molecular staging in nonsmall cell lung carcinoma. Cancer. 2005;104(7):1453–61.CrossRefPubMed
23.
Zurück zum Zitat Melfi FM, Lucchi M, Davinj F, Viti A, Fontanini G, Boldrini L, et al. Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. Eur J Cardiothorac Surg. 2008;34(1):181–6.CrossRefPubMed Melfi FM, Lucchi M, Davinj F, Viti A, Fontanini G, Boldrini L, et al. Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. Eur J Cardiothorac Surg. 2008;34(1):181–6.CrossRefPubMed
Metadaten
Titel
Topography of the sentinel node according to the affected lobe in lung cancer
verfasst von
J. M. Galbis-Caravajal
A. Lafuente-Sanchis
M. Estors-Guerrero
N. Martinez-Hernández
C. Fuster-Diana
A. Cremades
Á. Zúñiga
Publikationsdatum
27.01.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 7/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1615-4

Weitere Artikel der Ausgabe 7/2017

Clinical and Translational Oncology 7/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.